Page last updated: 2024-11-12

boc-d-fmk

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Boc-D-FMK: Caspase inhibitor and neuroprotective agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16760348
SCHEMBL ID17494190
MeSH IDM0452271

Synonyms (17)

Synonym
HY-13229
caspase inhibitor iii
boc-d-fmk
CS-0585
SCHEMBL17494190
c11h18fno5
634911-80-1
AKOS030526866
3-[[(tert-butoxy)carbonyl]amino]-5-fluoro-4-oxopentanoic acid methyl ester
A914720
caspase inhibitor iii - cas 634911-80-1
methyl 3-{[tert-butoxy(hydroxy)methylidene]amino}-5-fluoro-4-oxopentanoate
DTXSID50940205
methyl 5-fluoro-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxopentanoate
AT23478
MS-23708
BL181115

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Tirapazamine (TPZ) is a bioreductive agent that forms a toxic free radical in hypoxia."( Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
Reynolds, CP; Yang, B, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
"In a preliminary study, we found that benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD- fmk), unlike Boc-aspartyl(OMe)-fluoromethylketone (BocD-fmk), at usual dosage could not prevent genistein-induced apoptosis of p815 mastocytoma cells."( zVAD-fmk, unlike BocD-fmk, does not inhibit caspase-6 acting on 14-3-3/Bad pathway in apoptosis of p815 mastocytoma cells.
Baek, SJ; Jeong, BK; Jeong, JH; Jeong, SH; Kim, JM; Kim, TH; Kwon, TK; Park, BS; Park, HT; Yee, SB; Yoo, YH; Yoon, I, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (86.36)29.6817
2010's3 (13.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.27 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]